1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Friedreich Ataxia Global Clinical Trials Review, H1, 2016

Friedreich Ataxia Global Clinical Trials Review, H1, 2016

  • February 2016
  • -
  • Global Data
  • -
  • 58 pages

Friedreich Ataxia Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Friedreich Ataxia Global Clinical Trials Review, H1, 2016" provides an overview of Friedreich Ataxia clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Friedreich Ataxia Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Countries Contributing to Clinical Trials in Asia-Pacific 8
Top Five Countries Contributing to Clinical Trials in Europe 9
Top Countries Contributing to Clinical Trials in North America 10
Clinical Trials by G7 Countries: Proportion of Friedreich Ataxia to Central Nervous System Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by Phase 14
In Progress Trials by Phase 15
Clinical Trials by Trial Status 16
Clinical Trials by End Point Status 17
Subjects Recruited Over a Period of Time 18
Clinical Trials by Sponsor Type 19
Prominent Sponsors 20
Top Companies Participating in Friedreich Ataxia Therapeutics Clinical Trials 21
Prominent Drugs 22
Latest Clinical Trials News on Friedreich Ataxia 23
Nov 19, 2015: Retrotope announces opening of second clinical trial site for enrollment in Friedreich's ataxia clinical trial 23
Clinical Trial Profile Snapshots 24
Appendix 55
Abbreviations 55
Definitions 55
Research Methodology 56
Secondary Research 56
About GlobalData 57
Contact Us 57
Disclaimer 57
Source 58

List of Tables
Friedreich Ataxia Therapeutics, Global, Clinical Trials by Region, 2016* 5
Friedreich Ataxia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Friedreich Ataxia Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 8
Friedreich Ataxia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 9
Friedreich Ataxia Therapeutics Clinical Trials, North America, Top Countries, 2016* 10
Proportion of Friedreich Ataxia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 11
Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 12
Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 13
Friedreich Ataxia Therapeutics, Global, Clinical Trials by Phase, 2016* 14
Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 15
Friedreich Ataxia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 16
Friedreich Ataxia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 17
Friedreich Ataxia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 18
Friedreich Ataxia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 19
Friedreich Ataxia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 20
Friedreich Ataxia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 21
Friedreich Ataxia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 22

List of Figures
Friedreich Ataxia Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Friedreich Ataxia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 7
Friedreich Ataxia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 9
Friedreich Ataxia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 10
Proportion of Friedreich Ataxia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 11
Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 12
Friedreich Ataxia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 13
Friedreich Ataxia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 14
Friedreich Ataxia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 15
Friedreich Ataxia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 16
Friedreich Ataxia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 17
Friedreich Ataxia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 18
Friedreich Ataxia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 19
Friedreich Ataxia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 20
Friedreich Ataxia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 21
Friedreich Ataxia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 22
GlobalData Methodology 56

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glutamyl Aminopeptidase ...

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Leukotriene A 4 Hydrolase (LTA 4 Hydrolase or Leukotriene A(4) Hydrolase or LTA4H or EC 3.3.2.6) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leukotriene A 4 Hydrolase (LTA 4 Hydrolase ...

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.